



## Teleflex to Support Responding to Cardiac Arrest at ERC Congress, Resuscitation 2018, in Bologna, Italy from September 20th – 22nd

September 13, 2018

WAYNE, Pa.--(BUSINESS WIRE)--Sep. 13, 2018-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, today announced that during the ERC Congress, it will focus on the Arrow® EZ-IO® Intraosseous Access System and on the campaign “What could 10 seconds to vascular access mean to your cardiac arrest patient?”

Cardiac Arrest is one of the leading causes of mortality with an estimated 10% survival rate.<sup>1 2</sup>

Prompt treatment is essential for all cardiac arrest patients, whether a patient suffers an in-hospital cardiac arrest (IHCA) or an out-of-hospital cardiac arrest (OHCA). Studies have found an incidence rate of 84 OHCA per 100,000 population<sup>2</sup> and between 1.51-2.85 IHCA per 1,000 hospital patient admissions.<sup>3,4</sup> The incidence of cardiac arrest is a major health problem within Europe & the United States.

When a cardiac arrest occurs, rapid delivery of fluids and medication is key to treatment. Clinicians need fast methods of establishing vascular access, and IV access may be difficult or impossible due to cardiovascular collapse and environmental challenges.

The Arrow® EZ-IO® Intraosseous Vascular Access System from Teleflex is a fast, safe and effective solution in emergency situations<sup>5,6,7,8</sup>. The EZ-IO® System is indicated anytime vascular access is difficult to obtain in emergent, urgent, or medically necessary cases for up to 72 hours within Europe. The EZ-IO System is a difficult vascular access option that provides peripheral venous access with central venous catheter performance.<sup>7, 9, 10</sup>

While ERC is taking place, Teleflex will also host several educational sessions that will be run by the Teleflex Clinical & Medical Affairs team. These sessions take place on Friday 21<sup>st</sup> and Saturday 22<sup>nd</sup>. Some of the planned Teleflex Education programs include – “Humeral IO Masterclass”; “IO Emergency Scenario”; “Pediatric IO Masterclass”; and “Using IO in Resuscitation”.

Moreover, in collaboration with the Italian Red Cross and European Resuscitation Council, Teleflex will also host an innovative Helicopter Resuscitation Simulation Workshop titled “Helicopter Resuscitation: Let’s remember the airway & vascular access”. Healthcare professionals attending the ERC Congress can easily book his/her place at <http://TeleflexCMA.formstack.com/forms/helicopter>.

### About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose-driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit [teleflex.com](http://teleflex.com).

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsche® and Weck® – trusted brands united by a common sense of purpose.

### Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

1. Mozaffarian D, Benjamin EJ, Go AS, et al: on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. *Circulation*. 2015;131:e29–e322. DOI: 10.1161/CIR.000000000000152.
2. EuReCa ONE 27 Nations, ONE Europe, ONE Registry: A prospective one month analysis of out-of-hospital cardiac arrest outcomes in 27 countries in Europe, Volume 105, August 2016, Pages 188-195
3. Incidence and outcome of in-hospital cardiac arrest in Italy: a multicentre observational study in the Piedmont Region, *Resuscitation* [24 Jun 2017, 119:48-55]
4. Public Report Cards for In-Hospital Cardiac Arrest: Empowering the Public With Location-Specific Data, *Circulation*. Author manuscript; available in PMC 2016 Apr 21
5. Davidoff J, Fowler R, Gordon D, Klein G, Kovar J, Lozano M, Potkya J, Racht E, Saussy J, Swanson E, Yamada R, Miller L. Clinical evaluation of a novel intraosseous device for adults: prospective, 250-patient, multi-center trial. *JEMS* 2005;30(10):s20-3. Research sponsored by Teleflex Incorporated.
6. Montez D, Puga T, Miller LJ, et al. Intraosseous Infusions from the Proximal Humerus Reach the Heart in Less Than 3 Seconds in Human Volunteers. *Annals of Emergency Medicine* 2015;66(4S):S47. Research sponsored by Teleflex Incorporated.
7. Cooper BR, Mahoney PF, Hodgetts TJ, Mellor A. Intra-osseous access (EZ-IO®) for resuscitation: UK military combat experience. *J R Army Med Corps*. 2007;153(4):314-31 \* , \*\*
8. Teleflex Internal Data on file 2018

9. Hoskins SL, Nascimento P Jr., Lima RM, Espana-Tenorio, JM, Kramer GC. Pharmacokinetics of intraosseous and central venous drug delivery during cardiopulmonary resuscitation. Resuscitation 2011; doi:10.1016/j.resuscitation.2011.07.041. Research sponsored by Teleflex Incorporated. (preclinical study) \*, \*\*  
Hoskins SL, Zachariah BS, Copper N, Kramer GC. Comparison of intraosseous proximal humerus and sternal routes for drug delivery during
  10. CPR. Circulation 2007; 116:II\_993. Research sponsored by Teleflex Incorporated. (preclinical study) \*, \*\*
- \*Compared to single lumen Central Venous Catheters (CVCs).  
\*\*Based on Adult Proximal Humerus EZ-IO® insertion data.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180913005092/en/>

Source: Teleflex Incorporated

Teleflex Incorporated  
Jake Elguicze  
Treasurer and Vice President, Investor Relations  
610-948-2836